OptiNose
- Country
- 🇳🇴Norway
- Ownership
- Public
- Established
- 2000-01-01
- Employees
- 132
- Market Cap
- $155.3M
- Website
- http://www.optinose.com
- Introduction
OptiNose, Inc. operates as a pharmaceutical company. The firm engages in the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists. Its products include the XHANCE and ONZETRA Xsail. The company was founded by Per Gisle Djupesland and Helena Kyttari Djupesland in October 2000 and is headquartered in Yardley, PA.
A Study to Evaluate Change in Viral Load After OPN-019 in Adults With COVID-19
- Conditions
- Covid19
- Interventions
- Drug: OPN-019
- First Posted Date
- 2021-09-05
- Last Posted Date
- 2022-05-02
- Lead Sponsor
- Optinose US Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT05035576
- Locations
- 🇲🇽
Fundacion Santos y de la Garza Evia, I.B.P, Monterrey, N.l., Mexico
Study Evaluating the Efficacy and Safety of Intranasal Administration of OPN-375 in Subjects With Chronic Rhinosinusitis Without the Presence of Nasal Polyps
- Conditions
- Chronic Rhinosinusitis
- Interventions
- Drug: OPN-375
- First Posted Date
- 2019-05-23
- Last Posted Date
- 2023-12-21
- Lead Sponsor
- Optinose US Inc.
- Target Recruit Count
- 223
- Registration Number
- NCT03960580
- Locations
- 🇺🇸
BioSolutions Clinical Research Center, La Mesa, California, United States
🇺🇸Best Clinical Trials, New Orleans, Louisiana, United States
🇳🇿Optimal Clinical Trials, Auckland, New Zealand
Study Evaluating the Efficacy and Safety of Intranasal Administration of OPN-375 in Subjects With Chronic Rhinosinusitis With or Without the Presence of Nasal Polyps
- Conditions
- Chronic Rhinosinusitis
- Interventions
- Drug: OPN-375
- First Posted Date
- 2018-12-20
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- Optinose US Inc.
- Target Recruit Count
- 332
- Registration Number
- NCT03781804
- Locations
- 🇺🇸
Emory University MOT, Atlanta, Georgia, United States
🇺🇸Northwestern Memorial Hospital, Chicago, Illinois, United States
🇺🇸John Hopkins Hospital, Baltimore, Maryland, United States
OPN-375 Efficacy and Safety in Adolescents With Bilateral Nasal Polyps
- Conditions
- Bilateral Nasal Polyposis
- Interventions
- Drug: OPN-375
- First Posted Date
- 2018-11-20
- Last Posted Date
- 2023-09-26
- Lead Sponsor
- Optinose US Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT03747458
- Locations
- 🇺🇸
Arizona Allergy and Immunology Research, Gilbert, Arizona, United States
🇺🇸Children's Minnesota, Minneapolis, Minnesota, United States
🇺🇸Eastern Virginia Medical School - Otolaryngology, Norfolk, Virginia, United States
Efficacy & Safety of OPN-375 Adults With Bilateral Nasal Polyps Using Nasoendoscopic Video
- First Posted Date
- 2018-07-18
- Last Posted Date
- 2020-08-03
- Lead Sponsor
- Optinose US Inc.
- Target Recruit Count
- 11
- Registration Number
- NCT03591068
- Locations
- 🇺🇸
University of Colorado SOM, Department of Otolaryngology, Aurora, Colorado, United States
🇺🇸University of Texas Health Science Center at Houston, McGovern Medical School, Dept. of Otolaryngology, Head and Neck Surgery, Houston, Texas, United States
A Study to Compare the Bioavailability Intranasal Administration of 200 and 400 µg or 400 µg Alone of OPTINOSE™ FLUTICASONE With 440 µg of Flovent® HFA (Fluticasone Propionate) Inhalation Aerosol (Part 2)
- Conditions
- Mild to Moderate Asthma
- Interventions
- Drug: Flovent HFADrug: OPTINOSEâ„¢ FLUTICASONE
- First Posted Date
- 2014-10-17
- Last Posted Date
- 2016-02-03
- Lead Sponsor
- Optinose US Inc.
- Target Recruit Count
- 28
- Registration Number
- NCT02266927
- Locations
- 🇮🇪
Celerion, Belfast, Ireland
Efficacy and Safety Study of Intranasal Administration of 100, 200, and 400 μg of Fluticasone Propionate Using a Novel Bi-directional Device
- First Posted Date
- 2012-06-21
- Last Posted Date
- 2018-12-05
- Lead Sponsor
- Optinose US Inc.
- Target Recruit Count
- 323
- Registration Number
- NCT01624662
- Locations
- 🇺🇸
Allergy and Asthma Research Group, Eugene, Oregon, United States
🇺🇸Institute for Asthma and Allergy, Wheaton, Maryland, United States
🇺🇸University of Vermont, Burlington, Vermont, United States
Study Evaluating the Safety of Intranasal Administration of 400 μg of Fluticasone Propionate Twice a Day (BID) Using a Novel Bi-Directional Device in Subjects With Chronic Sinusitis With or Without Nasal Polyps
- Conditions
- Chronic Sinusitis With or Without Nasal Polyps
- Interventions
- First Posted Date
- 2012-06-19
- Last Posted Date
- 2016-08-29
- Lead Sponsor
- Optinose US Inc.
- Target Recruit Count
- 705
- Registration Number
- NCT01623323
- Locations
- 🇺🇸
InterMountain Ear Nose and Throat, Salt Lake City, Utah, United States
🇺🇸Institute for Asthma and Allergy, Wheaton, Maryland, United States
🇺🇸Texas Quest Medical Research, San Antonio, Texas, United States
Study Evaluating the Efficacy and Safety of Intranasal Administration of 100, 200, and 400 μg of Fluticasone Propionate Twice a Day (BID) Using a Novel Bi Directional Device in Subjects With Bilateral Nasal Polyposis Followed by an 8-Week Open-Label Extension Phase to Assess Safety
- First Posted Date
- 2012-06-19
- Last Posted Date
- 2018-12-26
- Lead Sponsor
- Optinose US Inc.
- Target Recruit Count
- 323
- Registration Number
- NCT01622569
- Locations
- 🇺🇸
California Allergy & Asthma Medical Group, Inc., Los Angeles, California, United States
🇺🇸Clinical Research Group of Montana, PLLC, Bozeman, Montana, United States
🇺🇸NU Feinberg School of Medicine Depart. of Otolaryngology-Head & Neck Surgery, Chicago, Illinois, United States
12-Month OL Intranasal Fluticasone Propionate BID Using OptiNose Device
- First Posted Date
- 2012-06-19
- Last Posted Date
- 2018-01-24
- Lead Sponsor
- Optinose US Inc.
- Target Recruit Count
- 223
- Registration Number
- NCT01623310
- Locations
- 🇺🇸
Exemplar Research, Fairmont, West Virginia, United States
🇺🇸Achieve Clinical Research, Birmingham, Alabama, United States
🇺🇸Sneeze Wheeze and Itch Associates, Normal, Illinois, United States